Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 621

1.

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.

van Helden EJ, Elias SG, Gerritse SL, van Es SC, Boon E, Huisman MC, van Grieken NCT, Dekker H, van Dongen GAMS, Vugts DJ, Boellaard R, van Herpen CML, de Vries EGE, Oyen WJG, Brouwers AH, Verheul HMW, Hoekstra OS, Menke-van der Houven van Oordt CW.

Eur J Nucl Med Mol Imaging. 2019 Nov 9. doi: 10.1007/s00259-019-04555-6. [Epub ahead of print]

PMID:
31705176
2.

A Clinical Feasibility Study To Image Angiogenesis in Patients With Arteriovenous Malformations Using 68Ga-RGD PET/CT.

Lobeek D, Bouwman FCM, Aarntzen EHJG, Molkenboer-Kuenen JDM, Flucke UE, Nguyen HL, Vikkula M, Boon LM, Klein W, Laverman P, Oyen WJG, Boerman OC, Terry SYA, SchultzeKool LJ, Rijpkema M.

J Nucl Med. 2019 Sep 13. pii: jnumed.119.231167. doi: 10.2967/jnumed.119.231167. [Epub ahead of print]

PMID:
31519800
3.

Emerging Vistas in Alpha Therapy-PSMA and Soft-Tissue Metastases.

Oyen WJG.

J Med Imaging Radiat Sci. 2019 Aug 22. pii: S1939-8654(19)30415-1. doi: 10.1016/j.jmir.2019.07.001. [Epub ahead of print] No abstract available.

PMID:
31447231
4.

EANM commitment towards involvement and engagement of patients and the public: learning from the UK experience.

Ribeiro AS, Lee M, Oyen WJG.

Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2218-2219. doi: 10.1007/s00259-019-04457-7. Epub 2019 Aug 2. No abstract available.

PMID:
31375856
5.

Optimal use of [18F]FDG-PET/CT in patients with fever or inflammation of unknown origin.

Mulders-Manders CM, Kouijzer IJ, Janssen MJ, Oyen WJ, Simon A, Bleeker-Rovers CP.

Q J Nucl Med Mol Imaging. 2019 Jul 1. doi: 10.23736/S1824-4785.19.03129-7. [Epub ahead of print]

PMID:
31271266
6.

Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art.

Perez-Lopez R, Tunariu N, Padhani AR, Oyen WJG, Fanti S, Vargas HA, Omlin A, Morris MJ, de Bono J, Koh DM.

Radiology. 2019 Aug;292(2):273-286. doi: 10.1148/radiol.2019181931. Epub 2019 Jun 25.

PMID:
31237493
7.

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.

Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, Oosting SF, Aarntzen EH, Brouwers AH, Kwee TC, Heskamp S, Hoekstra OS, Verheul H, van der Veldt AAM, de Vries EGE, Boerman OC, van der Graaf WTA, Oyen WJG, van Herpen CML.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1931-1939. doi: 10.1007/s00259-019-04358-9. Epub 2019 Jun 6.

8.

EANM Focus 1: one small step for two men, one giant leap for a specialty.

Fanti S, Oyen WJG.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1400-1401. doi: 10.1007/s00259-019-04326-3. Epub 2019 Apr 24. No abstract available.

PMID:
31016331
9.

Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas.

Vlenterie M, Oyen WJ, Steeghs N, Desar IME, Verheijen RB, Koenen AM, Grootjans W, DE Geus-Oei LF, VAN Erp NP, VAN DER Graaf WT.

Anticancer Res. 2019 Mar;39(3):1309-1316. doi: 10.21873/anticanres.13243.

PMID:
30842163
10.

Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy.

Bashir U, Tree A, Mayer E, Levine D, Parker C, Dearnaley D, Oyen WJG.

Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):901-907. doi: 10.1007/s00259-018-4249-z. Epub 2019 Jan 8.

11.

The EANM practical guidelines for sentinel lymph node localisation in oral cavity squamous cell carcinoma.

Giammarile F, Schilling C, Gnanasegaran G, Bal C, Oyen WJG, Rubello D, Schwarz T, Tartaglione G, Miller RN, Paez D, van Leeuwen FWB, Valdés Olmos RA, McGurk M, Delgado Bolton RC.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):623-637. doi: 10.1007/s00259-018-4235-5. Epub 2018 Dec 18.

12.

Consensus on molecular imaging and theranostics in prostate cancer.

Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O'Sullivan JM, Padhani AR, Schalken JA, Scher HI, Tombal B, van Moorselaar RJA, Van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG.

Lancet Oncol. 2018 Dec;19(12):e696-e708. doi: 10.1016/S1470-2045(18)30604-1.

PMID:
30507436
13.

Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models.

Burley TA, Da Pieve C, Martins CD, Ciobota DM, Allott L, Oyen WJG, Harrington KJ, Smith G, Kramer-Marek G.

J Nucl Med. 2019 Mar;60(3):353-361. doi: 10.2967/jnumed.118.216069. Epub 2018 Sep 13.

14.

Managing Nonmetastatic Castration-resistant Prostate Cancer.

Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS.

Eur Urol. 2019 Feb;75(2):285-293. doi: 10.1016/j.eururo.2018.07.035. Epub 2018 Aug 14. Review.

15.

Clinical predictors of escalating care in hepatic and renal cyst infection in autosomal dominant polycystic kidney and liver disease.

Lantinga MA, de Sévaux RGL, Gevers TJG, Oyen WJG, de Fijter JW, Soonawala D, Zietse R, Salih M, Casteleijn NF, Spithoven EM, Meijer E, Gansevoort RT, Drenth On Behalf Of The Dipak Consortium JPH.

Neth J Med. 2018 Jul;76(5):226-234.

16.

Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of 18F-FDG-PET based tumor segmentation in head and neck squamous cell carcinoma in a multicenter setting.

van den Bosch S, Dijkema T, Philippens MEP, Terhaard CHJ, Hoebers FJP, Kaanders JHAM, Oyen WJG.

Radiother Oncol. 2019 Jan;130:39-45. doi: 10.1016/j.radonc.2018.06.037. Epub 2018 Jul 10.

17.

Vascular infection with outside-in vertebral destruction in chronic Q fever.

Kouijzer IJE, Oyen WJG, Bleeker-Rovers CP.

Lancet Infect Dis. 2018 Jun;18(6):603. doi: 10.1016/S1473-3099(18)30272-X. No abstract available.

PMID:
29856356
18.

18F-fluorodeoxyglucose positron-emission tomography combined with computed tomography as a diagnostic tool in native valve endocarditis.

Kouijzer IJE, Berrevoets MAH, Aarntzen EHJG, de Vries J, van Dijk APJ, Oyen WJG, de Geus-Oei LF, Bleeker-Rovers CP.

Nucl Med Commun. 2018 Aug;39(8):747-752. doi: 10.1097/MNM.0000000000000864.

PMID:
29762262
19.

Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.

Hekman MCH, Rijpkema M, Aarntzen EH, Mulder SF, Langenhuijsen JF, Oosterwijk E, Boerman OC, Oyen WJG, Mulders PFA.

Eur Urol. 2018 Sep;74(3):257-260. doi: 10.1016/j.eururo.2018.04.026. Epub 2018 May 3.

PMID:
29730017
20.

Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study.

Hekman MC, Rijpkema M, Muselaers CH, Oosterwijk E, Hulsbergen-Van de Kaa CA, Boerman OC, Oyen WJ, Langenhuijsen JF, Mulders PF.

Theranostics. 2018 Mar 8;8(8):2161-2170. doi: 10.7150/thno.23335. eCollection 2018.

21.

In Vivo Characterization of 4 68Ga-Labeled Multimeric RGD Peptides to Image αvβ3 Integrin Expression in 2 Human Tumor Xenograft Mouse Models.

Lobeek D, Franssen GM, Ma MT, Wester HJ, Decristoforo C, Oyen WJG, Boerman OC, Terry SYA, Rijpkema M.

J Nucl Med. 2018 Aug;59(8):1296-1301. doi: 10.2967/jnumed.117.206979. Epub 2018 Apr 6.

22.

Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise.

Kouijzer IJE, van der Meer JWM, Oyen WJG, Bleeker-Rovers CP.

Clin Radiol. 2018 Jun;73(6):588-589. doi: 10.1016/j.crad.2018.02.004. Epub 2018 Mar 19. No abstract available.

PMID:
29567271
23.

Fever of Unknown Origin: the Value of FDG-PET/CT.

Kouijzer IJE, Mulders-Manders CM, Bleeker-Rovers CP, Oyen WJG.

Semin Nucl Med. 2018 Mar;48(2):100-107. doi: 10.1053/j.semnuclmed.2017.11.004. Epub 2017 Dec 8. Review.

24.

HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.

Martins CD, Da Pieve C, Burley TA, Smith R, Ciobota DM, Allott L, Harrington KJ, Oyen WJG, Smith G, Kramer-Marek G.

Clin Cancer Res. 2018 Apr 15;24(8):1853-1865. doi: 10.1158/1078-0432.CCR-17-2754. Epub 2018 Feb 6.

25.

18F-FDG PET/CT in Local Ablative Therapies: A Systematic Review.

Aarntzen EHJG, Heijmen L, Oyen WJG.

J Nucl Med. 2018 Apr;59(4):551-556. doi: 10.2967/jnumed.117.198184. Epub 2018 Jan 18.

26.

Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules.

de Koster EJ, de Geus-Oei LF, Dekkers OM, van Engen-van Grunsven I, Hamming J, Corssmit EPM, Morreau H, Schepers A, Smit J, Oyen WJG, Vriens D.

Endocr Rev. 2018 Apr 1;39(2):154-191. doi: 10.1210/er.2017-00133. Review.

PMID:
29300866
27.

The diagnostic value of 18F-FDG-PET/CT and MRI in suspected vertebral osteomyelitis - a prospective study.

Kouijzer IJE, Scheper H, de Rooy JWJ, Bloem JL, Janssen MJR, van den Hoven L, Hosman AJF, Visser LG, Oyen WJG, Bleeker-Rovers CP, de Geus-Oei LF.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):798-805. doi: 10.1007/s00259-017-3912-0. Epub 2017 Dec 19.

28.

Immuno-PET in Pontine Glioma: More Than Meets the Eye?

Oyen WJG, Jones C.

J Nucl Med. 2018 Apr;59(4):610-611. doi: 10.2967/jnumed.117.200527. Epub 2017 Dec 7. No abstract available.

29.

Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer.

Wong KH, Panek R, Dunlop A, Mcquaid D, Riddell A, Welsh LC, Murray I, Koh DM, Leach MO, Bhide SA, Nutting CM, Oyen WJ, Harrington KJ, Newbold KL.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):759-767. doi: 10.1007/s00259-017-3890-2. Epub 2017 Nov 21.

30.

Guidelines for quality control of PET/CT scans in a multicenter clinical study.

Hristova I, Boellaard R, Galette P, Shankar LK, Liu Y, Stroobants S, Hoekstra OS, Oyen WJG.

EJNMMI Phys. 2017 Sep 18;4(1):23. doi: 10.1186/s40658-017-0190-7.

31.

Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges.

Martins CD, Kramer-Marek G, Oyen WJG.

Expert Opin Drug Deliv. 2018 Feb;15(2):185-196. doi: 10.1080/17425247.2018.1378180. Epub 2017 Sep 12. Review.

PMID:
28893110
32.

Erratum to: Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.

Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Sundin A, Fanti S.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2150-2151. doi: 10.1007/s00259-017-3807-0. No abstract available.

PMID:
28856372
33.

Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.

Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Sundin A, Fanti S.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601. doi: 10.1007/s00259-017-3728-y. Epub 2017 May 25. Erratum in: Eur J Nucl Med Mol Imaging. 2017 Aug 30;:.

PMID:
28547177
34.

The Value of 18F-FDG PET/CT in Diagnosis and During Follow-up in 273 Patients with Chronic Q Fever.

Kouijzer IJE, Kampschreur LM, Wever PC, Hoekstra C, van Kasteren MEE, de Jager-Leclercq MGL, Nabuurs-Franssen MH, Wegdam-Blans MCA, Ammerlaan HSM, Buijs J, Geus-Oei LF, Oyen WJG, Bleeker-Rovers CP.

J Nucl Med. 2018 Jan;59(1):127-133. doi: 10.2967/jnumed.117.192492. Epub 2017 May 25.

35.

Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force.

Prior JO, Gillessen S, Wirth M, Dale W, Aapro M, Oyen WJG.

Eur J Cancer. 2017 May;77:127-139. doi: 10.1016/j.ejca.2017.01.030. Epub 2017 Apr 7.

36.

18F-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality.

Berrevoets MAH, Kouijzer IJE, Aarntzen EHJG, Janssen MJR, De Geus-Oei LF, Wertheim HFL, Kullberg BJ, Oever JT, Oyen WJG, Bleeker-Rovers CP.

J Nucl Med. 2017 Sep;58(9):1504-1510. doi: 10.2967/jnumed.117.191981. Epub 2017 Mar 23.

37.

The Predictive Value of Early In-Treatment 18F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non-Small Cell Lung Cancer.

Usmanij EA, Natroshvili T, Timmer-Bonte JNH, Oyen WJG, van der Drift MA, Bussink J, Geus-Oei LF.

J Nucl Med. 2017 Aug;58(8):1243-1248. doi: 10.2967/jnumed.116.185314. Epub 2017 Mar 23.

38.

Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma.

van den Bosch S, Dijkema T, Kunze-Busch MC, Terhaard CH, Raaijmakers CP, Doornaert PA, Hoebers FJ, Vergeer MR, Kreike B, Wijers OB, Oyen WJ, Kaanders JH.

BMC Cancer. 2017 Mar 21;17(1):208. doi: 10.1186/s12885-017-3195-7.

39.

Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic 18F Fluorodeoxyglucose PET.

Meijer TWH, de Geus-Oei LF, Visser EP, Oyen WJG, Looijen-Salamon MG, Visvikis D, Verhagen AFTM, Bussink J, Vriens D.

Radiology. 2017 May;283(2):547-559. doi: 10.1148/radiol.2016160329. Epub 2016 Nov 15.

PMID:
27846378
40.

Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor.

Desar IM, Braam PM, Kaal SE, Gerritsen WR, Oyen WJ, van der Graaf WT.

Acta Oncol. 2016 Dec;55(12):1510-1512. Epub 2016 Nov 8. No abstract available.

PMID:
27820978
41.

The Impact of Optimal Respiratory Gating and Image Noise on Evaluation of Intratumor Heterogeneity on 18F-FDG PET Imaging of Lung Cancer.

Grootjans W, Tixier F, van der Vos CS, Vriens D, Le Rest CC, Bussink J, Oyen WJ, de Geus-Oei LF, Visvikis D, Visser EP.

J Nucl Med. 2016 Nov;57(11):1692-1698. Epub 2016 Jun 9.

42.

Response Monitoring with [18F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases.

Heskamp S, Heijmen L, Gerrits D, Molkenboer-Kuenen JDM, Ter Voert EGW, Heinzmann K, Honess DJ, Smith DM, Griffiths JR, Doblas S, Sinkus R, Laverman P, Oyen WJG, Heerschap A, Boerman OC.

Mol Imaging Biol. 2017 Aug;19(4):540-549. doi: 10.1007/s11307-016-1021-2.

43.

International Multi-Specialty Delphi Survey: Identification of Diagnostic Criteria for Hepatic and Renal Cyst Infection.

Lantinga MA, Darding AJ, de Sévaux RG, Alam A, Bleeker-Rovers CP, Bobot M, Cornec-Le Gall E, Gevers TJ, Hassoun Z, Meijer E, Mrug M, Nevens F, Onuchic LF, Pei Y, Piccoli GB, Pirson Y, Rangan GK, Torra R, Visser FW, Jouret F, Kanaan N, Oyen WJ, Suwabe T, Torres VE, Drenth JP; Delphi collaborators.

Nephron. 2016;134(4):205-214. Epub 2016 Sep 3.

PMID:
27599120
44.

FDG-PET/CT Limited to the Thorax and Upper Abdomen for Staging and Management of Lung Cancer.

Arens AI, Postema JW, Schreurs WM, Lafeber A, Hendrickx BW, Oyen WJ, Vogel WV.

PLoS One. 2016 Aug 24;11(8):e0160539. doi: 10.1371/journal.pone.0160539. eCollection 2016.

45.

Targeted α-Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?

Oyen WJ, de Bono JS.

J Nucl Med. 2016 Dec;57(12):1838-1839. Epub 2016 Aug 18. No abstract available.

46.

The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with 18F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma.

Wong KH, Panek R, Welsh L, Mcquaid D, Dunlop A, Riddell A, Murray I, Du Y, Chua S, Koh DM, Bhide S, Nutting C, Oyen WJ, Harrington K, Newbold KL.

J Nucl Med. 2016 Dec;57(12):1843-1850. Epub 2016 Jul 14.

47.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.

Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.

PMID:
27380959
48.

A comparison of the diagnostic value of MRI and 18F-FDG-PET/CT in suspected spondylodiscitis.

Smids C, Kouijzer IJ, Vos FJ, Sprong T, Hosman AJ, de Rooy JW, Aarntzen EH, de Geus-Oei LF, Oyen WJ, Bleeker-Rovers CP.

Infection. 2017 Feb;45(1):41-49. doi: 10.1007/s15010-016-0914-y. Epub 2016 Jun 17.

49.

Performance of automatic image segmentation algorithms for calculating total lesion glycolysis for early response monitoring in non-small cell lung cancer patients during concomitant chemoradiotherapy.

Grootjans W, Usmanij EA, Oyen WJ, van der Heijden EH, Visser EP, Visvikis D, Hatt M, Bussink J, de Geus-Oei LF.

Radiother Oncol. 2016 Jun;119(3):473-9. doi: 10.1016/j.radonc.2016.04.039. Epub 2016 May 10.

PMID:
27178141
50.

Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside.

Kramer-Marek G, Oyen WJ.

J Nucl Med. 2016 Jul;57(7):996-1001. doi: 10.2967/jnumed.115.169540. Epub 2016 May 12. Review. No abstract available.

Supplemental Content

Support Center